Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    TBA 354
Previous Study | Return to List | Next Study

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02288481
Recruitment Status : Completed
First Posted : November 11, 2014
Last Update Posted : September 6, 2019
Sponsor:
Information provided by (Responsible Party):
Global Alliance for TB Drug Development

Tracking Information
First Submitted Date  ICMJE November 7, 2014
First Posted Date  ICMJE November 11, 2014
Last Update Posted Date September 6, 2019
Study Start Date  ICMJE January 2015
Actual Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 10, 2014)
The primary endpoint of the study will be the number and severity of treatment emergent adverse events (TEAEs) following single doses of TBA-354 and placebo. [ Time Frame: Day 1, 2, 4, 5, 6, 7, 14 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 10, 2014)
  • Pharmacokinetics of TBA-354 in plasma following single oral doses. Cmax, AUC0-24 [ Time Frame: Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144) ]
    Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours
  • Effect of food on the Pharmacokinetics parameters of TBA-354 in plasma following an intermediate single oral dose. Cmax, AUC0-24 [ Time Frame: Day 1 (Hour 0, 1, 2, 4, 6, 7, 8, 12, 16), Day 2 (Hour 20, 24, 30, 36, 42), Follow up (Hour 72, 96, 120, 144) ]
    Tmax: Time of the maximum drug concentration (obtained without interpolation). Cmax: Maximum observed drug concentration. AUC0-24: Area under concentration time curve 0 to 24 hours
  • Number of subjects/time points with abnormal findings in safety electrocardiogram [ Time Frame: Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144 ]
    Calculated in terms of QT corrected for heart rate according to Fridericia's corrected formula (QTcF) outliers (QTcF > 450, > 480, and > 500 msec; and change-from-baseline QTcF > 30 and > 60 msec).
  • Placebo-corrected safety electrocardiogram Change-from-baseline heart rate [ Time Frame: Screening; Day 1 (Hour 0, 1, 2, 4, 6, 8, 12, 16); Day 2 Hour 20, 24, 30, 36 and 48; Follow up Hour 144 ]
    Change-from-baseline heart rate, QT corrected for heart rate according to Fridericia's corrected formula (QTcF), PR, QRS, QT, and incidence of abnormal T-wave morphology from cardiodynamic electrocardiograms extracted from the pre-specified time points.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Official Title  ICMJE A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects
Brief Summary The objective of this study is to evaluate the safety and tolerability of single oral doses of TBA-354 when administered to healthy adult subjects.
Detailed Description

This is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in the United States. Six (6) cohorts of 8 subjects each (6 active and 2 placebo), with one cohort crossing over to assess food effect, are planned for evaluation. Subjects will participate in only one cohort.

Safety will be assessed throughout the study; serial ECGs and serial blood samples will be collected for the safety and PK assessment of TBA-354.

Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability and PK from the previous cohort has been demonstrated to permit proceeding to the next cohort. Upon review of cohort data, the Sponsor, in conjunction with the Principal Investigator, may decide to:

  1. Escalate dose as planned.
  2. Evaluate an intermediate dose level prior to proceeding to the next planned dose level if concerns arise from signs and symptoms that do not warrant ceasing escalation as described above.
  3. Repeat a given dose level in a new cohort of subjects.
  4. Halt the study.

Blinded interim PK analyses will be performed for the dose escalation decisions, to select the intermediate dose for the food effect cohort, and to reconsider the sampling time points as the study progresses.

Subjects will be housed in the Celerion clinic from at least 24 hours prior (from Day -2), until 48 hours after dosing. Subjects will return for subsequent follow up safety and PK assessments on Days 4 to 7 and will be contacted via a phone call for follow-up questioning about adverse events 7 days later (Study Day 14). One cohort will return after a washout of at least 14 days or five half-lives (whichever is longer) of their fasting dose to receive the same intermediate dose (TBD mg) under fed conditions.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Tuberculosis
Intervention  ICMJE
  • Drug: TBA-354
    TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
  • Other: Placebo
    Placebo Suspension
Study Arms  ICMJE
  • Experimental: Cohort 1 10 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 1 placebo
    Placebo Suspension
    Intervention: Other: Placebo
  • Experimental: Cohort 2 25 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 2 placebo
    Placebo Suspension
    Intervention: Other: Placebo
  • Experimental: Cohort 3 60 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 3 placebo
    Placebo Suspension
    Intervention: Other: Placebo
  • Experimental: Cohort 4 150 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 4 placebo
    Placebo Suspension
    Intervention: Other: Placebo
  • Experimental: Cohort 5 400 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 5 placebo
    Placebo Suspension
    Intervention: Other: Placebo
  • Experimental: Cohort 6 1000 mg TBA-354
    Intervention: Drug: TBA-354
  • Placebo Comparator: Cohort 6 placebo
    Placebo Suspension
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 10, 2014)
48
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE June 2015
Actual Primary Completion Date June 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

Subjects must fulfill all of the following inclusion criteria and none of the exclusion criteria to be eligible for participation in the study, unless otherwise specified. Subjects must continue to meet all inclusion criteria to be able to participate in the Food Effect study.

  1. Healthy adult male and females of non-childbearing potential, 19 to 50 years of age (inclusive) at the time of screening.
  2. Body mass index (BMI) ≥ 18.5 and ≤ 32.0 (kg/m2) and a body weight of no less than 50 kg.
  3. Medically healthy with no clinically significant screening results (e.g., laboratory profiles, medical histories, vital signs, electrocardiograms (ECGs), physical examination) as deemed by the Principal Investigator.
  4. No use of tobacco or nicotine containing products (including smoking cessation products), for a minimum of 6 months prior to dosing.
  5. Females of non-childbearing potential have undergone one of the following sterilization procedures at least 6 months prior to dosing:

    i. Hysteroscopic sterilization

    ii. Bilateral tubal ligation or bilateral salpingectomy

    iii. Hysterectomy

    iv. Bilateral oophorectomy

    v. or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serumfollicle-stimulating hormone (FSH) levels consistent with postmenopausal status at screening.

  6. Non-vasectomized males (or males vasectomized less than 120 days prior to study start), must agree to the following during study participation and for 90 days following the last administration of study drug:

    1. use a condom with spermicide while engaging in sexual activity or be sexually abstinent
    2. not donate sperm during this time.

    In the event the sexual partner is surgically sterile, use of a condom with spermicide is not necessary. None of the restrictions listed above are required for vasectomized males whose procedure was performed more than 120 days prior to study start.

  7. Willing to answer inclusion and exclusion criteria questionnaire at check-in.
  8. Subject understands study procedures and provides written informed consent for the trial.
  9. Be able to comply with the protocol and the assessments therein.

Exclusion Criteria:

Subjects will be excluded from the study if there is evidence of any of the following criteria at screening or check-in, as appropriate. Subjects must continue to meet none of the Exclusion Criteria in order to participate in the Food Effect study.

  1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  2. History of any illness that, in the opinion of the Principal Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
  3. Surgery within the past 90 days prior to dosing as determined by the Principal Investigator to be clinically relevant.
  4. History or presence of alcoholism or drug abuse within the past 2 years.
  5. Hypersensitive or idiosyncratic reactions to compounds related to TBA-354 (e.g., nitroimidazoles such as metronidazole, etc.).
  6. Female subjects who are pregnant or lactating.
  7. Positive results for the urine drug/alcohol screen at screening or check-in.
  8. Positive urine cotinine at screening.
  9. Positive results at screening for Human Immunodeficiency Virus (HIV), Hepatitis B Surface Antigen (HBsAg), or Hepatitis C antibodies (HCV).
  10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
  11. Heart rate is lower than 40 bpm or higher than 99 bpm at screening.
  12. Any clinically significant ECG abnormality at Screening (as deemed by the Principal Investigator and the Sponsor's Medical Monitor).

    NOTE: The following can be considered not clinically significant without consulting Sponsor's Medical Monitor:

    i. Mild first degree A-V block (P-R interval <0.23 sec)

    ii. Right or left axis deviation

    iii. Incomplete right bundle branch block

    iv. Isolated left anterior fascicular block (left anterior hemiblock) in younger athletic subjects

  13. QTcF interval >450 msec for males or >470 msec for females (the average value for the replicate ECG at screening and Check-In), or history of prolonged QT syndrome.
  14. Family history of Long-QT Syndrome or sudden death without a preceding diagnosis of a condition that could be causative of sudden death (such as known coronary artery disease, congestive heart failure or terminal cancer).
  15. History of one or any combination of, the following:

    1. Seizures or seizure disorders, (excluding febrile seizures of childhood).
    2. Brain trauma or brain surgery.
    3. Any serious disorder of the CNS or related neurological system, particularly one that may lower the seizure threshold.
  16. Use of any prescription medication within 14 days prior to dosing.
  17. Use of any over-the-counter (OTC) medication, including herbal products and vitamins, within the 7 days prior to dosing. Up to 2 grams per day of acetaminophen is allowed at the discretion of the Principal Investigator.
  18. Use of any drugs or substances known to be significant inhibitors of CYP enzymes and/or significant inhibitors or substrates of P-gp and/or OATP within 14 days prior to the first dose of study drug.
  19. Use of any drugs or substances known to be inducers of CYP enzymes and/or P-gp, including St. John's Wort, within 28 days prior to the first dose of study drug.
  20. Use of any drugs or substance known to lower the seizure threshold.
  21. Blood donation or significant blood loss within 56 days prior to dosing.
  22. Plasma donation within 7 days prior to dosing.
  23. Participation in another clinical trial within 28 days prior to dosing.
  24. Prior treatment with investigational products PA-824 or OPC-67683.
  25. Consumption of the following prior to dosing period:

    1. Alcohol 48 hours prior to dosing
    2. Grapefruit/Mandarin Oranges 10 days prior to dosing
    3. Caffeine/Xanthine 24 hours prior to dosing
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02288481
Other Study ID Numbers  ICMJE TBA-354-CL-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Global Alliance for TB Drug Development
Study Sponsor  ICMJE Global Alliance for TB Drug Development
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Michael Gartner, MD Celerion
PRS Account Global Alliance for TB Drug Development
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP